A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
Rickerts
V
V
Klinikum der Johann Wolfgang Goethe-Universität, Zentrum der Inneren Medizin, Infektionsambulanz, Haus 68, Theodor-Stern-Kai 7, Frankfurt, Germany.
Bickel
M
M
Tews
J
J
Jacobi
V
V
Staszewski
S
S
D000005:Abdomen; D000273:Adipose Tissue / Q000000981:diagnostic imaging; D000328:Adult; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects; D008060:Lipodystrophy / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D010078:Oxazines / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed; D015215:Zidovudine / Q000009:adverse effects
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; C098320:efavirenz